Clinical Pharmacokinetics of Aztreonam
- 1 March 1988
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 14 (3) , 148-155
- https://doi.org/10.2165/00003088-198814030-00003
Abstract
Aztreonam (azthreonam) is practically completely absorbed after intramuscular injection. After intravenous injection plasma concentrations follow a 2-compartment open model, with a t½α of 0.20 hours. Volume of distribution at steady-state (Vdss) after intravenous or intramuscular injection is about 0.16 L/kg (0.42 L/kg for the free drug). After oral administration less than 1% of the drug is absorbed. Over a large dosage range plasma concentrations increase linearly with dose. No accumulation occurs after multiple dosing. Plasma binding in healthy subjects is about 56% and is not concentration dependent. Diffusion into tissues is generally slow, and the ratio between mean tissue and plasma concentration seems to depend mainly on the composition of the tissue. In inflamed meninges, penetration of aztreonam into CSF is more rapid than with uninflamed meninges. Diffusion through the placenta is poor, as is diffusion into breast milk. The main route of elimination of aztreonam is by the kidney, partly by active tubular excretion, but this can be inhibited by probenecid. Extrarenal clearance is probably due to excretion by the liver. Metabolism occurs to a very limited extent. Total plasma clearance in healthy adults is about 140 ml/min (8.4 L/h) or 2 ml/min/kg (0.12 L/h/kg), and terminal half-life is 1.7 hours. In children clearance is similar to that in adults when expressed as a function of body weight, but in neonates, especially in low birthweight infants, it is less [about 1 ml/min/kg (0.06 L/h/kg)]. In various disease states the Vdss of aztreonam is not appreciably different from that found in healthy individuals. However, half-life is greatly dependent on renal function, and in anuric patients is 8 to 10 hours. Haemodialysis is modestly effective in removing aztreonam, but long term peritoneal dialysis contributes little to plasma clearance In alcoholic cirrhosis of the liver extrarenal clearance of aztreonam is significantly diminished.Keywords
This publication has 41 references indexed in Scilit:
- The effect of probenecid on the renal tubular excretion of benzylpenicillin.British Journal of Clinical Pharmacology, 1988
- Saturation of the tubular excretion of beta-lactam antibiotics.British Journal of Clinical Pharmacology, 1988
- The relation between plasma and tissue concentrations of antibiotics. Description of a methodJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Pharmacokinetics of aztreonam in elderly male volunteers.British Journal of Clinical Pharmacology, 1985
- Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokineticsKidney International, 1984
- Aztreonam concentrations in human prostatic tissueAntimicrobial Agents and Chemotherapy, 1984
- Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjectsAntimicrobial Agents and Chemotherapy, 1983
- Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjectsJournal of Antimicrobial Chemotherapy, 1981
- Cefazolin and cephradine: Relationship between serum concentrations and tissue contents in miceInfection, 1978
- Blood-Brain and CSF Barriers to Penicillin and Related Organic AcidsArchives of Neurology, 1966